Press reviews
2024-11-14
Transplantation of faecal microbiota: a new weapon against type 2 diabetes?
Endocrinology and Metabolism
Type 2 diabetes (T2D) is a chronic disease that affects millions of people worldwide. In fact, it represents a major public health challenge. This is all the more true given that current evidence suggests that conventional treatments are not always effective and may be associated with undesirable side-effects. Given the limitations of these treatments, the search for therapeutic alternatives is a priority.
Fecal microbiota transplantation (FMT), which involves introducing healthy intestinal flora into a patient, has shown promising potential in the treatment of certain diseases (Clostridium difficile infection, inflammatory bowel disease, etc.). With this in mind, this study looked at the use of FMT to treat T2DM, to assess its effectiveness and limitations.FMT as an intervention in type 2 diabetes: a clinical study
21 patients with type 2 diabetes treated with metformin were included in the study and divided into three groups:
- FMT from healthy, lean donors ;
- Probiotic (Lactobacillus delbrueckii LB-14) ;
- Placebo.
The following parameters were measured over a 12-week period: anthropometric variables, blood glucose and HbA1c levels, insulin sensitivity using the HOMA-IR model and the composition of each participant's faecal microbiota.
These studies show that :
- FMT does not significantly improve insulin sensitivity or HbA1c in patients with T2DM.
- A moderate increase in HbA1c was observed in patients who received FMT (+0.25%, p = 0.041), but no significant change in glucose or HbA1c levels was observed between the groups.
- The composition of faecal microbiota did not differ between the three treatment groups. However, the microbiota profile changed mainly in favour of the donor species, with no significant impact on insulin sensitivity.
Microbiota transplantation as a therapeutic approach for type II diabetes
This study demonstrates that FMT from healthy, lean donors is not associated with a clinically significant improvement in insulin sensitivity or reduction in HbA1c in patients with T2D. Although temporary changes in the composition of the microbiota were observed, no lasting metabolic effect was observed. This study, limited by a small sample size of 21 participants and some heterogeneity in baseline patient characteristics, suggests that further research is needed to better identify the potential of FMT in T2D, in particular by adjusting the frequency and choice of donor bacteria.
Breast cancer is one of the leading causes of death among women worldwide. Despite therapeutic advances, conventional treatments are often limited by major side-effects and disease resistance, making it necessary to develop more targeted and effective strategies.
In this context, immunotherapy, which aims to stimulate the patient's own immune system, is attracting growing interest. While promising results have been obtained with monotherapy, the combination of immunotherapies is emerging as a way of improving treatment efficacy and overcoming resistance. This study analyses the impact of combined immunotherapies in the treatment of breast cancer.
A meta-analysis to assess the efficacy of combined immunotherapies
This study, based on a systematic review and meta-analysis of phase I to IV clinical trials, assesses the efficacy of combined immunotherapies in the treatment of breast cancer. The studies included compared the effects of combined therapies with those of a single immunotherapy, analysing two main indicators: overall survival (OS) and progression-free survival (PFS).
The results showed that combination immunotherapies significantly improved OS and PFS compared with monotherapies, confirming their potential in real-life clinical settings for breast cancer patients.
Combined immunotherapies: towards a new era in the treatment of breast cancer
This research shows that combined immunotherapies are a promising therapeutic option in the treatment of breast cancer. By targeting both tumour cells and the tumour microenvironment, these therapies offer a solution for optimising the immune response, overcoming resistance to treatment, reducing the risk of recurrence and thus prolonging patient survival. These advances also pave the way for more effective personalised treatments for breast cancer.
Sepsis is an acute inflammatory response to infection, often associated with high mortality despite advances in intensive care. Identifying reliable predictive biomarkers is therefore essential to improve patient management and reduce mortality. Among the biomarkers explored, homocysteine (Hcy) appears to be a potential indicator, due to its role in oxidative stress, endothelial dysfunction and inflammation, essential mechanisms in the pathophysiology of sepsis. This study explores the association between Hcy levels and short-term mortality in patients with sepsis.
Can homocysteine levels predict short-term mortality in patients with sepsis?
The results showed no significant association between Hcy levels and short-term mortality in patients with sepsis. However, subgroup analysis revealed a significant association between elevated Hcy levels and an increased risk of mortality in Chinese patients with sepsis. The absence of a significant correlation between Hcy levels and mortality in non-Asian patients suggests an ethical influence between the relationship between Hcy and mortality in sepsis.
Homocysteine, a new biomarker for predicting mortality in sepsis
Although the study did not confirm the general usefulness of Hcy as a biomarker of mortality in sepsis, it does highlight its potential as a prognostic marker for certain populations, particularly Asian patients. Further research is needed to better understand these ethnic differences and to assess whether Hcy could become a personalised biomarker for predicting mortality in specific populations.
Pancreatic cancer is one of the most aggressive digestive cancers, with a prognosis that is often poor due to late diagnosis and ineffective treatment. While the risk factors do include active smoking, the influence of passive smoking remains controversial. This study therefore explored the association between passive smoking and the risk of pancreatic cancer in order to gain a better understanding of this potential relationship.
What is the link between passive smoking and pancreatic cancer?
14 studies including 5,560 patients with pancreatic cancer were selected and analysed. A random-effects model was used to combine the data from the studies and assess the relative risk associated with passive smoking. Subgroup analyses were also carried out (case-control vs. cohort, study quality, smoking status of participants, duration and frequency of exposure to passive smoking, etc.).
This study demonstrates firstly that exposure to passive smoke is associated with a moderate risk of pancreatic cancer. The results also show that the association is present in both current smokers and non-smokers, indicating that exposure to passive smoking is a risk factor. Furthermore, this association was observed in both children and adults, suggesting that the risk is significant at every stage of life. Finally, these studies suggest that the frequency of exposure to passive smoking is another important factor. People exposed regularly or daily to passive smoking have a higher risk of pancreatic cancer.
Passive smoking: An increased risk of pancreatic cancer not to be ignored
This study clearly shows that passive smoking represents a significant risk factor for pancreatic cancer, particularly when exposure is regular or daily. The results underline the importance of stepping up prevention strategies to limit such exposure, particularly among children and adolescents.
2024-11-12
Atrial Fibrillation and COVID-19: A Concerning Association Not to Be Overlooked
Infectiology
The COVID-19 pandemic
has revealed significant effects of the virus on the cardiovascular system,
particularly with the emergence of serious cardiac complications such as atrial
fibrillation (AF). This cardiac arrhythmia, often associated with severe clinical
outcomes, appears to increase mortality risk in COVID-19 patients, whether
pre-existing or newly diagnosed. With the exact relationship between COVID-19
and AF still uncertain, this study analyzed the prevalence and mortality risks
associated with AF in COVID-19 patients.
What is the Link Between Atrial Fibrillation and COVID-19?
To explore this association, 80 studies involving over 39 million COVID-19 patients were selected. A random-effects model was used to combine findings and estimate prevalence and mortality rates. Subgroup analyses were conducted by age, COVID-19 severity, sample size, and geographical region, followed by sensitivity analysis to validate result robustness.
This study reveals an overall AF prevalence of 10.5% in COVID-19 patients with pre-existing AF and 10.3% for newly diagnosed AF. Prevalence is notably higher in patients aged 65 and older (14.4%) compared to younger patients (6.4%), as well as in those with severe COVID-19 cases (14.1% vs. 5.2% in non-severe cases).
Moreover, an increased mortality risk (HR of 1.83) was observed in COVID-19 patients with AF, especially among those with newly diagnosed AF (HR of 3.47). Geographical analyses indicate higher mortality in Asian patients (HR: 5.33), followed by North Americans (HR: 2.01) and Europeans (HR: 1.68).
This study highlights a high prevalence of AF in COVID-19 patients, especially among the elderly and those with severe cases. Both pre-existing and newly diagnosed AF are linked to increased mortality risk, particularly in Asian patients and those with new-onset AF. These findings underscore the importance of proactive management of AF in COVID-19 patients to improve outcomes. This association also emphasizes the need for targeted strategies, such as preventive anticoagulation, to reduce thromboembolic risk. Further research is needed to refine these approaches and tailor care to the specific needs of COVID-19 patients with AF.
What is the Link Between Atrial Fibrillation and COVID-19?
To explore this association, 80 studies involving over 39 million COVID-19 patients were selected. A random-effects model was used to combine findings and estimate prevalence and mortality rates. Subgroup analyses were conducted by age, COVID-19 severity, sample size, and geographical region, followed by sensitivity analysis to validate result robustness.
This study reveals an overall AF prevalence of 10.5% in COVID-19 patients with pre-existing AF and 10.3% for newly diagnosed AF. Prevalence is notably higher in patients aged 65 and older (14.4%) compared to younger patients (6.4%), as well as in those with severe COVID-19 cases (14.1% vs. 5.2% in non-severe cases).
Moreover, an increased mortality risk (HR of 1.83) was observed in COVID-19 patients with AF, especially among those with newly diagnosed AF (HR of 3.47). Geographical analyses indicate higher mortality in Asian patients (HR: 5.33), followed by North Americans (HR: 2.01) and Europeans (HR: 1.68).
A Strong Association Between Atrial Fibrillation and COVID-19
This study highlights a high prevalence of AF in COVID-19 patients, especially among the elderly and those with severe cases. Both pre-existing and newly diagnosed AF are linked to increased mortality risk, particularly in Asian patients and those with new-onset AF. These findings underscore the importance of proactive management of AF in COVID-19 patients to improve outcomes. This association also emphasizes the need for targeted strategies, such as preventive anticoagulation, to reduce thromboembolic risk. Further research is needed to refine these approaches and tailor care to the specific needs of COVID-19 patients with AF.
2024-11-12
Pediatrics
Epilepsy is a chronic neurological disorder that affects approximately 1% of
the global population, including 1 in 200 children. Managing pediatric epilepsy
often relies on anticonvulsant monotherapy, but the optimal drug choice remains
a topic of debate. Levetiracetam (LEV) and carbamazepine (CBZ) are both common
treatments, each with specific benefits and distinct side effect profiles.
This study analyzed the efficacy and safety of LEV and CBZ in children and adolescents with focal epilepsy, aiming to provide clearer therapeutic guidance.
This study pooled data from four randomized controlled trials, including 381 patients, using robust statistical models to evaluate the effects of each treatment. Key outcome measures include seizure freedom and frequency, adverse event frequency (all types and those leading to treatment discontinuation), and incidence of dermatological adverse events.
Findings indicate that:
The results position LEV as a promising option for monotherapy in pediatric focal epilepsy, especially for children sensitive to dermatological side effects or requiring a reduction in seizure frequency. However, further research is needed to deepen the understanding of the efficacy and safety of these antiepileptic medications in children and adolescents and to refine recommendations for this population.
This study analyzed the efficacy and safety of LEV and CBZ in children and adolescents with focal epilepsy, aiming to provide clearer therapeutic guidance.
Levetiracetam: A More Advantageous Option in Epileptic Children?
This study pooled data from four randomized controlled trials, including 381 patients, using robust statistical models to evaluate the effects of each treatment. Key outcome measures include seizure freedom and frequency, adverse event frequency (all types and those leading to treatment discontinuation), and incidence of dermatological adverse events.
Findings indicate that:
- Both treatments showed similar efficacy in achieving seizure freedom and total seizure prevention.
- LEV demonstrated a significantly lower frequency of seizures and dermatological adverse events compared to CBZ.
- No significant difference was observed in the overall rate of adverse events or events leading to treatment discontinuation.
Levetiracetam as a Promising Therapy in Pediatric Epilepsy
The results position LEV as a promising option for monotherapy in pediatric focal epilepsy, especially for children sensitive to dermatological side effects or requiring a reduction in seizure frequency. However, further research is needed to deepen the understanding of the efficacy and safety of these antiepileptic medications in children and adolescents and to refine recommendations for this population.
Castration-resistant prostate cancer (mCRPC) presents a major challenge
for healthcare professionals. Despite recent advances, treatment options for
this deadly disease remain limited. CAR-T therapy, which involves modifying
immune cells to specifically target and destroy cancer cells, has shown
promise; however, its effectiveness against solid tumors has yet to be
confirmed.
This study explores the potential of CAR-T cells in treating mCRPC,
specifically targeting the Prostate Stem Cell Antigen (PSCA). The primary
objective is to assess the efficacy, safety, and potential effects of this
approach in addressing the unmet therapeutic needs of patients with mCRPC.
In this study, 14 patients with significant PSCA expression and advanced mCRPC were divided into three cohorts, each receiving increasing doses of PSCA CAR-T cells, with some patients undergoing prior lymphodepletion (LD):
The results showed an antitumor response in 4 out of 14 patients, with a 30% reduction in prostate-specific antigen levels. Dynamic changes in the composition of peripheral blood T cells confirmed immune system activation. Radiographic improvements in some participants indicated a reduction in tumor mass. Additionally, a moderate cytokine release syndrome was observed, without severe neurological or immune toxicity. Overall, CAR-T therapy was well tolerated, with grade 3 cystitis being the most common DLT.
These findings demonstrate that CAR-T cells targeting the PSCA antigen represent a promising therapeutic approach for mCRPC. Besides inducing an effective antitumor response, the safety profile is acceptable. These results lay the groundwork for optimizing dosages and combination strategies to enhance CAR-T cell persistence. Future directions for this therapy could include adjustments in lymphodepletion, development of next-generation CAR-T cells, and exploration of additional antigen targets to maximize benefits for patients resistant to current treatments.
CAR-T PSCA Therapy: Results And Initial Clinical Observations
In this study, 14 patients with significant PSCA expression and advanced mCRPC were divided into three cohorts, each receiving increasing doses of PSCA CAR-T cells, with some patients undergoing prior lymphodepletion (LD):
- Cohort DL1: 100 million CAR-T cells without lymphodepletion.
- Cohort DL2: 100 million CAR-T cells with standard lymphodepletion.
- Cohort DL3: 100 million CAR-T cells with reduced lymphodepletion.
The results showed an antitumor response in 4 out of 14 patients, with a 30% reduction in prostate-specific antigen levels. Dynamic changes in the composition of peripheral blood T cells confirmed immune system activation. Radiographic improvements in some participants indicated a reduction in tumor mass. Additionally, a moderate cytokine release syndrome was observed, without severe neurological or immune toxicity. Overall, CAR-T therapy was well tolerated, with grade 3 cystitis being the most common DLT.
Toward Optimizing CAR-T Therapies in mCRPC
These findings demonstrate that CAR-T cells targeting the PSCA antigen represent a promising therapeutic approach for mCRPC. Besides inducing an effective antitumor response, the safety profile is acceptable. These results lay the groundwork for optimizing dosages and combination strategies to enhance CAR-T cell persistence. Future directions for this therapy could include adjustments in lymphodepletion, development of next-generation CAR-T cells, and exploration of additional antigen targets to maximize benefits for patients resistant to current treatments.
Prostate cancer is the second most common
cancer among men, and its treatment continues to pose challenges due to its
increasing incidence and resistance to therapies, particularly under hypoxic
conditions. Hypoxia—an oxygen-deficient state—frequently occurs in solid
tumors, contributing to therapy resistance, disease progression, and metastasis
formation. Hypoxia-inducible factors, especially HIF-1α, are central to cancer cells’ adaptation to
hypoxia, promoting growth and survival. Targeting HIF-1α with specific inhibitors is
therefore a promising therapeutic strategy in the battle against prostate
cancer.
This study investigated the potential of Yardenone 2, a marine-derived HIF-1α inhibitor, as a treatment for advanced prostate cancer.
Yardenone 2: A Promising HIF-1α Inhibitor?
The researchers examined the impact of Yardenone 2 on HIF-1α stability, its nuclear localization, the expression of target genes, and the proliferation of prostate cancer cells under hypoxic conditions. They conducted experiments using prostate cancer cell lines (PC3), normal prostate epithelial cells, and a renal cancer cell line. Following exposure to hypoxic conditions, they measured HIF-1α’s expression and localization. HIF-1α target gene expression was also observed alongside cell proliferation rates. Additionally, the researchers compared Yardenone 2 with the current standard treatment, Docetaxel, to assess its efficacy and safety.
Results from this study indicate that Yardenone 2 effectively destabilizes HIF-1α at the protein level, reduces its nuclear localization, and thus limits its transcriptional activity under hypoxia.
Furthermore, this inhibitor specifically impacts the expression of HIF-1α target genes without affecting other gene expressions, demonstrating high specificity.
The findings also suggest that Yardenone 2 selectively inhibits PC3 cell proliferation under hypoxic conditions without compromising cell viability.
The comparative analysis finally reveals that, under hypoxic conditions, Yardenone 2 shows superior efficacy to Docetaxel by inhibiting cell proliferation (cytostatic action) without causing significant cellular toxicity.
The results of this study suggest that Yardenone 2 could become a novel, targeted therapy for advanced prostate cancer. With its cytostatic action specifically targeting hypoxic cells, Yardenone 2 stands out as a promising candidate for developing new prostate cancer treatments, especially for cases resistant to standard therapies. Further research, including clinical trials, could confirm its efficacy and open the door to new therapeutic options for patients.
This study investigated the potential of Yardenone 2, a marine-derived HIF-1α inhibitor, as a treatment for advanced prostate cancer.
Yardenone 2: A Promising HIF-1α Inhibitor?
The researchers examined the impact of Yardenone 2 on HIF-1α stability, its nuclear localization, the expression of target genes, and the proliferation of prostate cancer cells under hypoxic conditions. They conducted experiments using prostate cancer cell lines (PC3), normal prostate epithelial cells, and a renal cancer cell line. Following exposure to hypoxic conditions, they measured HIF-1α’s expression and localization. HIF-1α target gene expression was also observed alongside cell proliferation rates. Additionally, the researchers compared Yardenone 2 with the current standard treatment, Docetaxel, to assess its efficacy and safety.
Results from this study indicate that Yardenone 2 effectively destabilizes HIF-1α at the protein level, reduces its nuclear localization, and thus limits its transcriptional activity under hypoxia.
Furthermore, this inhibitor specifically impacts the expression of HIF-1α target genes without affecting other gene expressions, demonstrating high specificity.
The findings also suggest that Yardenone 2 selectively inhibits PC3 cell proliferation under hypoxic conditions without compromising cell viability.
The comparative analysis finally reveals that, under hypoxic conditions, Yardenone 2 shows superior efficacy to Docetaxel by inhibiting cell proliferation (cytostatic action) without causing significant cellular toxicity.
Yardenone 2: A promising new therapeutic approach in prostate cancer treatment
The results of this study suggest that Yardenone 2 could become a novel, targeted therapy for advanced prostate cancer. With its cytostatic action specifically targeting hypoxic cells, Yardenone 2 stands out as a promising candidate for developing new prostate cancer treatments, especially for cases resistant to standard therapies. Further research, including clinical trials, could confirm its efficacy and open the door to new therapeutic options for patients.
2024-11-08
Oncology
Clinical stage II A/B seminomas, a
type of testicular cancer, are typically managed with chemotherapy or
radiotherapy. While effective, these treatments are associated with significant
short- and long-term toxicities, which increase the risks of cardiovascular
complications and secondary cancers. In this context, retroperitoneal lymph
node dissection (RPLND)—a surgical procedure that removes retroperitoneal lymph
nodes—has emerged as a potentially less toxic alternative. Drawing from a
recent systematic review and meta-analysis, this article examines the efficacy
and safety of RPLND as a first-line treatment for clinical stage II A/B
seminomas.
This study analyzed data from 331 patients with clinical stage II A/B seminomas. The main outcomes assessed were recurrence rates, two-year recurrence-free survival, and complication rates.
The study findings indicate that RPLND showed a moderate recurrence rate (17.69%) and a high two-year recurrence-free survival rate (81%). With a low incidence of severe complications—9.16% for minor complications and 8.83% for complications classified as Clavien-Dindo grade > 2—RPLND demonstrated acceptable safety for carefully selected patients. The main side effects included a low rate of ejaculatory dysfunction (7.01%) and minimal blood loss during surgery (averaging 105.91 mL).
The findings from this study suggest that RPLND is a viable therapeutic option for patients with clinical stage II A/B seminomas, offering high survival rates, along with low recurrence and complication rates compared to traditional treatments (radiotherapy or chemotherapy). However, variations in surgical techniques and the absence of randomized trials limit widespread recommendations. Further research is needed to directly compare the effectiveness of RPLND with standard treatments and assess its long-term impact on survival and quality of life. Additionally, identifying predictive factors for success could facilitate a more precise selection of candidates for this procedure, paving the way for personalized treatment strategies.
Is RPLND an effective and safe option for treating clinical stage II A/B seminomas?
This study analyzed data from 331 patients with clinical stage II A/B seminomas. The main outcomes assessed were recurrence rates, two-year recurrence-free survival, and complication rates.
The study findings indicate that RPLND showed a moderate recurrence rate (17.69%) and a high two-year recurrence-free survival rate (81%). With a low incidence of severe complications—9.16% for minor complications and 8.83% for complications classified as Clavien-Dindo grade > 2—RPLND demonstrated acceptable safety for carefully selected patients. The main side effects included a low rate of ejaculatory dysfunction (7.01%) and minimal blood loss during surgery (averaging 105.91 mL).
Retroperitoneal lymph node dissection: a viable therapeutic alternative for clinical stage II A/B seminomas
The findings from this study suggest that RPLND is a viable therapeutic option for patients with clinical stage II A/B seminomas, offering high survival rates, along with low recurrence and complication rates compared to traditional treatments (radiotherapy or chemotherapy). However, variations in surgical techniques and the absence of randomized trials limit widespread recommendations. Further research is needed to directly compare the effectiveness of RPLND with standard treatments and assess its long-term impact on survival and quality of life. Additionally, identifying predictive factors for success could facilitate a more precise selection of candidates for this procedure, paving the way for personalized treatment strategies.
2024-11-08
Antibiotic therapy for acute otitis media in children: preventing complications or overprescribing?
Pediatrics
Acute otitis media (AOM) in children is a common infection that often leads to the use of antibiotics to prevent serious infectious complications. Guidelines often recommend an ‘active surveillance’ approach, but fear of complications such as mastoiditis leads many clinicians to prescribe antibiotics routinely. However, the actual impact of antibiotics in preventing infectious complications of AOM remains open to debate. In this context, this study was initiated to clarify the impact of these treatments on the prevention of infectious complications.
Methodology and results
This study compared the use of antibiotics in children with AOM with careful observation and monitoring or placebo. The main outcome measures were serious infectious complications (mastoiditis, meningitis) and non-serious infectious complications (eardrum perforation, contralateral otitis media, recurrence of AOM).
Firstly, this research showed that the use of antibiotics significantly reduced the risk of acute mastoiditis, with a relative risk reduction of 52%. On the other hand, although antibiotics appeared to reduce certain non-serious side-effects such as tympanic perforation, they increased the risk of undesirable effects (diarrhoea, skin rashes), with a relative increase in risk of 49%. The researchers also found no clear evidence of a protective effect of antibiotics against serious infectious complications (intracranial complications).
A cautious approach to prescribing antibiotics
The results of this study indicate that antibiotics can reduce the risk of certain serious complications of AOM in children, such as mastoiditis. However, their use also entails an increased risk of adverse effects and antibiotic resistance. These observations underline the need not to systematically prescribe antibiotics, but to adopt a more targeted approach based on each child's individual risk profile. Further research into risk factors will enable antibiotic prescriptions to be optimised, so as to maximise the benefits while minimising the risks.
2024-11-07
Memory Immunity Against COVID-19: A Less Effective Response in Organ Transplant Recipients?
Infectiology
Vaccination against COVID-19 has transformed
the fight against the pandemic. However, the immune response to vaccination is
not uniform across all individuals. Solid organ transplant recipients are among
the high-risk groups for severe COVID-19 due to their weakened immune systems,
compromised by immunosuppressive medications required to prevent graft
rejection. This study examines the role of SARS-CoV-2-specific memory B cells
in post-vaccination immunity, assessing their capacity to induce a protective
response in this vulnerable population.
Comparative
Study in Transplant Patients and Immunocompetent Individuals
The study analyzed immune responses in 148 organ transplant recipients and 32
immunocompetent individuals who received multiple booster doses. Concurrently,
a randomized controlled trial (RCT) was conducted with 25 transplant patients
who had not developed neutralizing antibodies (NAb) after three vaccine doses. Two
immunosuppressive strategies were compared:
The results of this study indicated that:
- Standard exposure ;
- Reduced exposure to calcineurin inhibitors.
The results of this study indicated that:
- Transplant recipients show a weaker and delayed memory immune response (after the fourth dose) compared to immunocompetent individuals;
- SARS-CoV-2-specific memory B cells are strongly correlated with neutralizing antibody levels;
- SARS-CoV-2-specific memory B cells and IL-2-producing T cells serve as strong predictive markers for seroconversion and protection against severe COVID-19 in transplant recipients;
- Shifting from a standard to a reduced immunosuppressive strategy supports a more robust and faster immune response after the fourth vaccine dose.
Key Role
of SARS-CoV-2-Specific Memory B Cells in Protecting Transplant Patients Against
COVID-19
This study highlights the central role of SARS-CoV-2-specific memory B cells in
protecting organ transplant recipients from COVID-19. It also confirms that
adjusting immunosuppressive treatments could enhance vaccination efficacy in
these at-risk patients. Future studies on alternative immunosuppression
regimens and/or adapted vaccination strategies may offer solutions for better
immune protection, particularly by promoting long-term immunity in at-risk
patients.
Pancreatic
ductal carcinoma is one of the most aggressive cancers, often resistant to
conventional treatments. Most patients are diagnosed at an advanced stage,
rendering traditional therapies ineffective. Therefore, developing new
therapeutic strategies is a priority to improve patient outcomes.
Among promising approaches, oncolytic virotherapy, which uses modified viruses to destroy cancer cells, is gaining attention. Specifically, the minute virus of mice (MVMp), known for its tropism for cancer cells, may represent a novel strategy to target pancreatic tumors.
This article examines the oncolytic potential of MVMp, detailing its mechanisms of action and its impact on pancreatic cancer cells.
MVMp infection has been studied in vitro and in vivo, using immunodeficient and immunocompetent mouse models. The virus’s effectiveness was observed in both mesenchymal and epithelial pancreatic cell lines, as well as in human-derived pancreatic cancer cells. The effects of MVMp were evaluated based on several parameters: induction of cancer cell death, modification of the tumor microenvironment, and activation of the immune system.
Firstly, these studies confirm the virus’s selectivity. MVMp preferentially infects mesenchymal-type pancreatic cells.
MVMp infection is also associated with increased cytotoxicity. The virus induces apoptosis in mesenchymal cells with minimal impact on epithelial cells. Finally, in immunocompetent mice, MVMp slows tumor growth and extends survival while triggering an immune response characterized by the infiltration of cytotoxic T cells and activated macrophages into the tumor.
This study highlights MVMp's potential as an oncolytic agent for pancreatic cancer treatment. Its specificity for mesenchymal tumor cells, its ability to induce cancer cell death, and its capacity to stimulate the immune system make it a promising therapeutic candidate, particularly for the most aggressive forms of pancreatic cancer. More broadly, these findings provide a robust foundation for a precision medicine approach in patients with tumors exhibiting a mesenchymal profile. Additional studies, especially those exploring combinations with immunotherapies, could further enhance MVMp's therapeutic efficacy in treating resistant cancers.
Among promising approaches, oncolytic virotherapy, which uses modified viruses to destroy cancer cells, is gaining attention. Specifically, the minute virus of mice (MVMp), known for its tropism for cancer cells, may represent a novel strategy to target pancreatic tumors.
This article examines the oncolytic potential of MVMp, detailing its mechanisms of action and its impact on pancreatic cancer cells.
MVMp: A Virus Targeting the Most Aggressive Cancer Cells
MVMp infection has been studied in vitro and in vivo, using immunodeficient and immunocompetent mouse models. The virus’s effectiveness was observed in both mesenchymal and epithelial pancreatic cell lines, as well as in human-derived pancreatic cancer cells. The effects of MVMp were evaluated based on several parameters: induction of cancer cell death, modification of the tumor microenvironment, and activation of the immune system.
Firstly, these studies confirm the virus’s selectivity. MVMp preferentially infects mesenchymal-type pancreatic cells.
MVMp infection is also associated with increased cytotoxicity. The virus induces apoptosis in mesenchymal cells with minimal impact on epithelial cells. Finally, in immunocompetent mice, MVMp slows tumor growth and extends survival while triggering an immune response characterized by the infiltration of cytotoxic T cells and activated macrophages into the tumor.
The Minute Virus of Mice as a Therapy for Aggressive Pancreatic Cancer
This study highlights MVMp's potential as an oncolytic agent for pancreatic cancer treatment. Its specificity for mesenchymal tumor cells, its ability to induce cancer cell death, and its capacity to stimulate the immune system make it a promising therapeutic candidate, particularly for the most aggressive forms of pancreatic cancer. More broadly, these findings provide a robust foundation for a precision medicine approach in patients with tumors exhibiting a mesenchymal profile. Additional studies, especially those exploring combinations with immunotherapies, could further enhance MVMp's therapeutic efficacy in treating resistant cancers.
Castration-resistant prostate cancer (CRPC) presents a major therapeutic challenge in men due to the resistance that develops against standard treatments like docetaxel. Therefore, finding approaches to overcome this chemoresistance is a top priority. In this context, researchers are investigating vitamin D, known for its anti-inflammatory and anticancer properties.
This article explores the impact of vitamin D analogues (Xe4MeCF3) on docetaxel efficacy and chemoresistance in prostate cancer.
To evaluate the efficacy of Xe4MeCF3, researchers used docetaxel-resistant prostate cancer cell lines, as well as 3D spheroid models to simulate the tumor microenvironment. Xe4MeCF3 was tested alone and in combination with docetaxel.
The results of this study indicate:
By specifically targeting CRPC progression pathways, Xe4MeCF3, combined with docetaxel, represents a promising therapeutic approach for CRPC patients. Xe4MeCF3 has shown superior efficacy not only in restoring sensitivity to docetaxel but also in inhibiting tumor growth, with a broader therapeutic window. However, additional clinical trials are necessary to validate this strategy and pave the way for innovative treatment options for CRPC.
This article explores the impact of vitamin D analogues (Xe4MeCF3) on docetaxel efficacy and chemoresistance in prostate cancer.
What effect does Xe4MeCF3 have on CRPC cells?
To evaluate the efficacy of Xe4MeCF3, researchers used docetaxel-resistant prostate cancer cell lines, as well as 3D spheroid models to simulate the tumor microenvironment. Xe4MeCF3 was tested alone and in combination with docetaxel.
The results of this study indicate:
- An enhanced expression of the vitamin D receptor at doses 100 times lower than those of natural vitamin D;
- A restoration of sensitivity to docetaxel. The combination of Xe4MeCF3 and docetaxel overcomes initial treatment resistance by stimulating a specific cytotoxic response in tumor cells.
- A reduction in tumor growth in the context of resistance. In combination with docetaxel, Xe4MeCF3 significantly reduces tumor size and increases apoptosis markers, demonstrating potential clinical application.
- Targeting key signaling pathways involved in hypoxia and androgen signaling, further enhancing the impact of Xe4MeCF3 on disease control.
By specifically targeting CRPC progression pathways, Xe4MeCF3, combined with docetaxel, represents a promising therapeutic approach for CRPC patients. Xe4MeCF3 has shown superior efficacy not only in restoring sensitivity to docetaxel but also in inhibiting tumor growth, with a broader therapeutic window. However, additional clinical trials are necessary to validate this strategy and pave the way for innovative treatment options for CRPC.
2024-11-05
The role of macrophages in pancreatic cancer: A new resistance mechanism revealed?
Oncology
Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), represents one of the deadliest forms of cancer. Despite scientific advances, the five-year survival rate remains alarmingly low, often below 10%. This aggressiveness is largely attributed to the tumor microenvironment (TME), which not only influences tumor growth but also its resistance to treatments. Macrophages, key players in innate immunity, play an ambiguous role within the TME. Often seen as accomplices in tumor progression, they can also act as active resistors against tumors.
This study was initiated to characterize the mechanisms by which macrophages could be transformed into antitumor allies in pancreatic cancer. In particular, attention was given to DYRK1B kinase, an enzyme in pancreatic cancer cells, whose inhibition may alter macrophage behavior, steering them toward a tumoricidal action.
In this study, researchers used murine PDAC models and human cell lines to evaluate the impact of DYRK1B inhibition on macrophage activity. Murine pancreatic cancer cells (mKpc4) with genetic ablation of Dyrk1b (KO) were generated and transplanted alongside control cells. To analyze changes within the tumor microenvironment (TME), RNA sequencing and immunofluorescence techniques were applied to the tumors. Finally, they studied how DYRK1B inhibition influences the macrophages' capacity to phagocytize tumor cells.
The main findings of this study are as follows:
This study suggests that DYRK1B plays a key role in modulating the TME in pancreatic cancer. By promoting macrophage suppression and shielding tumor cells from phagocytosis, DYRK1B actively contributes to treatment resistance. Inhibiting DYRK1B thus opens promising avenues to leverage the immune potential of macrophages in PDAC, particularly by reprogramming these cells toward an active response against tumors. These findings encourage further research on molecular inhibitors of DYRK1B, currently in clinical trials. This approach could improve PDAC treatment by enhancing innate immunity, making therapies more effective against this challenging cancer.
This study was initiated to characterize the mechanisms by which macrophages could be transformed into antitumor allies in pancreatic cancer. In particular, attention was given to DYRK1B kinase, an enzyme in pancreatic cancer cells, whose inhibition may alter macrophage behavior, steering them toward a tumoricidal action.
Role of DYRK1B in controlling macrophages
In this study, researchers used murine PDAC models and human cell lines to evaluate the impact of DYRK1B inhibition on macrophage activity. Murine pancreatic cancer cells (mKpc4) with genetic ablation of Dyrk1b (KO) were generated and transplanted alongside control cells. To analyze changes within the tumor microenvironment (TME), RNA sequencing and immunofluorescence techniques were applied to the tumors. Finally, they studied how DYRK1B inhibition influences the macrophages' capacity to phagocytize tumor cells.
The main findings of this study are as follows:
- DYRK1B ablation results in slower tumor growth in vivo in mice, despite increased proliferation in vitro.
- DYRK1B KO tumors exhibit a significant accumulation of macrophages with an M1 polarization profile (pro-inflammatory and tumoricidal), enhancing their antitumor potential.
- DYRK1B inhibition led to increased CD24 expression on the surface of tumor cells, thereby limiting phagocytosis by macrophages.
- The inhibition of DYRK1B, combined with mTOR-targeted therapies and chemotherapy, significantly extends survival in aggressive pancreatic cancer models.
DYRK1B: a promising therapeutic target in pancreatic cancer treatment
This study suggests that DYRK1B plays a key role in modulating the TME in pancreatic cancer. By promoting macrophage suppression and shielding tumor cells from phagocytosis, DYRK1B actively contributes to treatment resistance. Inhibiting DYRK1B thus opens promising avenues to leverage the immune potential of macrophages in PDAC, particularly by reprogramming these cells toward an active response against tumors. These findings encourage further research on molecular inhibitors of DYRK1B, currently in clinical trials. This approach could improve PDAC treatment by enhancing innate immunity, making therapies more effective against this challenging cancer.
Source(s) :
Brichkina, A., et al. (2024). DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer. Gut.
;
Cardiovascular diseases are the leading cause of mortality worldwide, with risk factors such as hypertension, abnormal lipid profiles, and chronic inflammation playing a major role in their progression. In this context, adopting a gluten-free diet (GFD) is gaining interest for its potential effects on cardiovascular health, though its precise impact remains to be clarified, especially among celiac and non-celiac patients with cardiovascular diseases. This study examines the possible benefits of a GFD for these patients.
To evaluate these effects, a systematic review and meta-analysis of 19 studies (2000 to 2022) was conducted. The study includes both celiac and non-celiac patients, measuring changes in blood lipid levels, blood pressure, and inflammatory markers (C-reactive protein, CRP). The diet’s efficacy was assessed at baseline and after adopting the GFD, observing the following outcome variables: fasting glucose, insulin, HbA1c, HOMA-IR, total cholesterol, LDL-C, HDL-C, triglycerides, blood pressure, and C-reactive protein.
The analysis results reveal significant beneficial effects of the GFD on certain cardiovascular parameters:
The results of this study suggest that a gluten-free diet may have a significant beneficial impact on cardiovascular health. While promising, further research is necessary to better understand its long-term effects, especially in non-celiac patients. Tailoring dietary choices to individual needs could also maximize its benefits in the prevention and treatment of cardiovascular diseases.
What are the effects of a Gluten-Free Diet on cardiac risk factors?
To evaluate these effects, a systematic review and meta-analysis of 19 studies (2000 to 2022) was conducted. The study includes both celiac and non-celiac patients, measuring changes in blood lipid levels, blood pressure, and inflammatory markers (C-reactive protein, CRP). The diet’s efficacy was assessed at baseline and after adopting the GFD, observing the following outcome variables: fasting glucose, insulin, HbA1c, HOMA-IR, total cholesterol, LDL-C, HDL-C, triglycerides, blood pressure, and C-reactive protein.
The analysis results reveal significant beneficial effects of the GFD on certain cardiovascular parameters:
- An average increase in HDL-C of 4.80 mg/dl in celiac patients after 48 weeks on a GFD;
- An average reduction in systolic blood pressure by 2.96 mmHg;
- A decrease in CRP levels by 0.40 mg/l, indicating reduced chronic inflammation.
The Gluten-Free Diet as a preventive tool for heart health
The results of this study suggest that a gluten-free diet may have a significant beneficial impact on cardiovascular health. While promising, further research is necessary to better understand its long-term effects, especially in non-celiac patients. Tailoring dietary choices to individual needs could also maximize its benefits in the prevention and treatment of cardiovascular diseases.
